Beam Therapeutics appointed Eric Foster as chief commercial officer to lead commercial organization and strategy across its hematology and genetic-disease franchises. Beam explicitly linked the role to preparations for a potential 2027 launch of…
TELA Bio disclosed that Roberto Cuca stepped down as chief financial officer, chief operating officer, corporate secretary and principal financial officer effective August 31. The filing treats the departure as a termination without cause….
Invivyd appointed board chair Marc W. Elia chief executive officer and principal executive officer, effective August 30. CFO William Duke Jr., who previously held the principal-executive-officer designation, remains CFO, principal financial officer and principal…
Vivace Therapeutics named Craig Gibbs as chief executive officer and appointed Ellen Lubman as chief business and strategy officer, formalizing a leadership transition from founder Sofie Qiao as the company advances VT3989 toward a…
Eascra Biotech announced Andrew Goodearl, Ph.D., as chief scientific officer, adding an executive with biotherapeutics and genetic-medicine research experience to the early-stage nanomedicine company. The company did not identify a predecessor, appointment effective date,…
Alto Neuroscience promoted Nicholas “Nick” Smith from chief financial and business officer to president and chief financial officer, effective August 26, 2026, broadening his remit across corporate strategy while founder Amit Etkin remains chief…
Outlook Therapeutics appointed Kevin Lundquist chief financial officer, treasurer, principal financial officer and principal accounting officer effective September 1. Lawrence A. Kenyon will leave those roles the same day, remain a non-executive employee through…
PDS Biotechnology terminated chief operating officer Stephan Toutain without cause and removed him from the role on August 21 while implementing a board-approved reduction affecting approximately 36% of employees. The company said the restructuring…
Mirai Bio appointed Kate Torchilin as permanent chief executive officer and president after she had served as interim CEO since November 2025, promoted Jagesh Shah to chief scientific officer, and appointed Jeff Luber as…
Septerna appointed Rajiv Patni, M.D., as chief medical officer as SEP-479 advances through Phase I. Patni most recently served as chief executive officer of Judo Bio and previously held CMO or R&D leadership roles…
